

Standing Order for Dispensing and Administration of COVID-19 Vaccine: 2025-2026

This standing order authorizes qualified pharmacy personnel pursuant to 105 CMR 700.004(B)(6) to dispense and administer COVID-19 vaccine in Massachusetts to all eligible persons as described below.

Procedure

- 1) Assess for Need of Vaccination.
- 2) Screen for Contraindications and Precautions.
Contraindications:
 - A severe allergic reaction (e.g., anaphylaxis) after a previous dose of the COVID-19 vaccine or to a component of the COVID-19 vaccinePrecautions:
 - A diagnosed non-severe allergy to a component of the COVID-19 vaccine.
 - Non-severe, immediate (onset less than 4 hours) allergic reaction after administration. of a previous dose of one COVID-19 vaccine type, if receiving the same vaccine type.
 - Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.
 - Moderate to severe acute illness, with or without fever.
- 3) Provide Vaccine Information Statements.
- 4) Prepare to Administer Vaccine.
 - Verify that the label on the vaccine states 2025-2026 Formula.
 - Choose the needle gauge, needle length, and injection site.
- 5) Administer COVID-19 Vaccine

For intramuscular administration

- MNEXSPIKE (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
Dispense single 0.2 mL dose for:
 - o Individuals 12 years of age and older
 - o For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of MNEXSPIKE at least 3 months after the last dose of COVID-19 vaccineDirections for use: Administer MNEXSPIKE as a single 0.2 mL dose

OR

- SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
 - a. Individuals 5 years of age through 11 years of age
Dispense single 0.25 mL dose, irrespective of COVID-19 vaccination status.
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose $\geq$ 2 months after the last dose of COVID-19 vaccineDirection for use: Administer SPIKEVAX 0.25 mL dose
 - OR**
 - b. Individuals 12 years of age and older
Dispense single 0.5 mL dose, irrespective of COVID-19 vaccination status.
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose $\geq$ 2 months after the last dose of COVID-19 vaccineDirection for use: Administer SPIKEVAX 0.5 mL dose

OR

- COMIRNATY (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
 - a. Individuals 5 years of age through 11 years of age
Dispense single 0.3 mL dose supplied in vials with blue caps and labeled with blue borders
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine

Directions for use: Administer COMIRNATY as a single 0.3 mL dose

OR

- b. Individuals 12 years of age and older
Dispense single 0.3 mL dose supplied in prefilled syringes labeled with gray borders
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine

Direction for use: Administer COMIRNATY as a single 0.3 mL dose

OR

- NUVAXOVID (COVID-19 Vaccine, Adjuvanted) injectable suspension, 2025-2026 Formula
Dispense single 0.5 mL dose for:
 - o Individuals 12 years of age and older
 - o For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of NUVAXOVID at least 2 months after the last dose of COVID-19 vaccine

Directions for use: Administer NUVAXOVID as a single 0.5 mL dose

6) Document the Vaccination.

7) Be Prepared to Manage Medical Emergencies.

8) Report Adverse Events to the Vaccine Adverse Event Reporting System (VAERS).

Physician's Signature

Date

Physician's Name and MA License No. (print legibly)